Cargando…

A broadly neutralizing germline-like human monoclonal antibody against dengue virus envelope domain III

Dengue is the most widespread vector-borne viral disease caused by dengue virus (DENV) for which there are no safe, effective drugs approved for clinical use. Here, by using sequential antigen panning of a yeast antibody library derived from healthy donors against the DENV envelop protein domain III...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Dan, Zhu, Zhongyu, Li, Shun, Deng, Yongqiang, Wu, Yanling, Zhang, Nana, Puri, Vinita, Wang, Chunyu, Zou, Peng, Lei, Cheng, Tian, Xiaolong, Wang, Yulu, Zhao, Qi, Li, Wei, Prabakaran, Ponraj, Feng, Yang, Cardosa, Jane, Qin, Chengfeng, Zhou, Xiaohui, Dimitrov, Dimiter S., Ying, Tianlei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6615639/
https://www.ncbi.nlm.nih.gov/pubmed/31242272
http://dx.doi.org/10.1371/journal.ppat.1007836
Descripción
Sumario:Dengue is the most widespread vector-borne viral disease caused by dengue virus (DENV) for which there are no safe, effective drugs approved for clinical use. Here, by using sequential antigen panning of a yeast antibody library derived from healthy donors against the DENV envelop protein domain III (DIII) combined with depletion by an entry defective DIII mutant, we identified a cross-reactive human monoclonal antibody (mAb), m366.6, which bound with high affinity to DENV DIII from all four DENV serotypes. Immunogenetic analysis indicated that m366.6 is a germline-like mAb with very few somatic mutations from the closest VH and Vλ germline genes. Importantly, we demonstrated that it potently neutralized DENV both in vitro and in the mouse models of DENV infection without detectable antibody-dependent enhancement (ADE) effect. The epitope of m366.6 was mapped to the highly conserved regions on DIII, which may guide the design of effective dengue vaccine immunogens. Furthermore, as the first germline-like mAb derived from a naïve antibody library that could neutralize all four DENV serotypes, the m366.6 can be a tool for exploring mechanisms of DENV infection, and is a promising therapeutic candidate.